BeyondSpring Inc.
https://www.beyondspringpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From BeyondSpring Inc.
Asia Deal Watch: Ocumension Obtains Chinese Rights To Eight Alcon Products
Also deals involving WuXi/Medigene, Eisai/Seed, Genor/Two River/Third Rock Ventures, ImmuneOnco/Instil, Biocytogen/Ideaya, Takeda/Dr Reddy’s/Zydus/Mankind and deals in brief.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: J&J’s Spravato on track for blockbuster status; US uptake of Rezzdifra held up by payers; CNS drugs are surprisingly valuable; obesity rules large cap stocks; and Legend buyout rumors validate China biotech.
Legend Buyout Report Boosts, Validates China Biotech
A reported buyout bid for Legend Biotech has delivered a much needed shot of confidence to the Chinese biotech sector, despite not being confirmed. Amid a shifting environment, Hengrui also sees globalization as essential to its future.
Will US Clinical Study Diversity Guidance Cloud Chinese Firms’ Prospects For Going Global?
The latest FDA guidance will have profound impact to Chinese biotech sector at a time when going global and a US approval is vital to its very survival.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Dalian Wanchunbulin Pharmaceuticals Ltd.
- Seed Therapeutics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice